[
  {
    "ts": "2025-08-11T13:10:00+00:00",
    "headline": "3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates",
    "summary": "Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.",
    "url": "https://finance.yahoo.com/news/3-biotech-stocks-likely-outpace-131000878.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "c987577f-1dd4-3e17-a754-ba23b3bdfe0a",
      "content": {
        "id": "c987577f-1dd4-3e17-a754-ba23b3bdfe0a",
        "contentType": "STORY",
        "title": "3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates",
        "description": "",
        "summary": "Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.",
        "pubDate": "2025-08-11T13:10:00Z",
        "displayTime": "2025-08-11T13:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/huVQAxApMqB.EnhvDFmmKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AOhBEAisdCF50xeLb4f6kA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-biotech-stocks-likely-outpace-131000878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-11T11:00:00+00:00",
    "headline": "Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update",
    "summary": "Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 Doses selected for KT-621 Phase 2b trials in AD and asthma, which are on track to initiate in 4Q25 and 1Q26, respectively KT-579 (IRF5) IND-enabling studies ongoing, with Phase 1 clinical trial expected to start in early",
    "url": "https://finance.yahoo.com/news/kymera-therapeutics-announces-second-quarter-110000567.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "4aa0e7bd-4d95-33ce-bd22-d2299f221aca",
      "content": {
        "id": "4aa0e7bd-4d95-33ce-bd22-d2299f221aca",
        "contentType": "STORY",
        "title": "Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update",
        "description": "",
        "summary": "Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 Doses selected for KT-621 Phase 2b trials in AD and asthma, which are on track to initiate in 4Q25 and 1Q26, respectively KT-579 (IRF5) IND-enabling studies ongoing, with Phase 1 clinical trial expected to start in early",
        "pubDate": "2025-08-11T11:00:00Z",
        "displayTime": "2025-08-11T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/169434dff20c8469427f97dd8a0a5d56",
          "originalWidth": 1313,
          "originalHeight": 304,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uEabNw3GRx8i_LaBZRCR6w--~B/aD0zMDQ7dz0xMzEzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/169434dff20c8469427f97dd8a0a5d56.cf.webp",
              "width": 1313,
              "height": 304,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JivX9hwzZwEx.phfDK.FCA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/169434dff20c8469427f97dd8a0a5d56.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kymera-therapeutics-announces-second-quarter-110000567.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kymera-therapeutics-announces-second-quarter-110000567.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KYMR"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-11T08:15:00+00:00",
    "headline": "Company News for Aug 11, 2025",
    "summary": "Companies In The News Are: GILD, TTD, TXRH, GEN.",
    "url": "https://finance.yahoo.com/news/company-news-aug-11-2025-081500680.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "8603dd82-3928-3448-bce4-1393d9fcb54d",
      "content": {
        "id": "8603dd82-3928-3448-bce4-1393d9fcb54d",
        "contentType": "STORY",
        "title": "Company News for Aug 11, 2025",
        "description": "",
        "summary": "Companies In The News Are: GILD, TTD, TXRH, GEN.",
        "pubDate": "2025-08-11T08:15:00Z",
        "displayTime": "2025-08-11T08:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V0K9NHfyQItlfJrmH40Oow--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZZlN12HiCVB5ZUMKhsVieA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/company-news-aug-11-2025-081500680.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/company-news-aug-11-2025-081500680.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "TXRH"
            },
            {
              "symbol": "GEN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-11T06:00:00+00:00",
    "headline": "Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.",
    "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
    "url": "https://www.barrons.com/articles/gilead-sciences-stock-price-gild-biotech-buy-cc8088b6?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "21e99a61-5271-353e-b06d-95859eec457a",
      "content": {
        "id": "21e99a61-5271-353e-b06d-95859eec457a",
        "contentType": "STORY",
        "title": "Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.",
        "description": "",
        "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
        "pubDate": "2025-08-11T06:00:00Z",
        "displayTime": "2025-08-11T06:00:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/21e99a61-5271-353e-b06d-95859eec457a/gilead-stock-is-closing-in-on.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/ae32e1b56ae3550c5439d053d46aa665",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zqURVtKialhePO7pACW41g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/ae32e1b56ae3550c5439d053d46aa665.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.r8GVuhX581LOZYX7PT0Zg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/ae32e1b56ae3550c5439d053d46aa665.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/gilead-sciences-stock-price-gild-biotech-buy-cc8088b6?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "XBI"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "IBB"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]